AJ1-11095

Ajax, aiming for a better JAK drug, raises $95M to begin first tests
BioPharma Dive
Tue, 05/14/24 - 11:37 am
JAK inhibitors
Ajax Therapeutics
myelofibrosis
AJ1-11095